Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 8:58 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1753–1776 of 1,838 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Placebo- C Clear all

Conditions: Coronavirus Disease (COVID-19)
Interventions: V590, Placebo; Biological · Other
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 232 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 7
States / cities: Tempe, Arizona • Miami, Florida • South Miami, Florida + 4 more

Conditions: Excessive Daytime Sleepiness
Interventions: ORX142 Tablets, Placebo Tablets; Drug · Other
Lead sponsor: Centessa Pharmaceuticals (UK) Limited; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 208 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 3
States / cities: Lincoln, Nebraska • Eatontown, New Jersey • New York, New York

Conditions: Hepatitis, Hepatitis C
Interventions: Filibuvir, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 288 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 30
States / cities: Anaheim, California • Coronado, California • La Jolla, California + 22 more

Conditions: Alzheimer's Disease
Interventions: Vitamin E, Vitamin C, and Alpha-lipoic Acid, Coenzyme Q, Placebo capsules, Placebo wafers; Drug
Lead sponsor: National Institute on Aging (NIA); NIH
Eligibility: 60 Years to 85 Years
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 13
States / cities: Tucson, Arizona • Irvine, California • La Jolla, California + 10 more

Conditions: C3 Glomerulopathy, Immune-complex-membranoproliferative Glomerulonephritis
Interventions: LNP023; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 12 Years to 100 Years
Enrollment: 225 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2036
U.S. locations: 5
States / cities: Aurora, Colorado • Lawrenceville, Georgia • Iowa City, Iowa + 2 more

Conditions: Amyotrophic Lateral Sclerosis
Interventions: CNM-Au8, Matching Placebo; Drug
Lead sponsor: Merit E. Cudkowicz, MD; Other
Eligibility: 18 Years and older
Enrollment: 161 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Progressive Supranuclear Palsy (PSP)
Interventions: antisense oligonucleotide, placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 40 Years to 75 Years
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 3
States / cities: La Jolla, California • Rochester, Minnesota • Nashville, Tennessee

Conditions: Climacteric; Menorrhagia, Menopausal, Menopause
Interventions: 50 mg PYC and then placebo, 100 mg PYC and then placebo, Placebo and then 50 mg PYC, Placebo and then 100 mg PYC; Dietary Supplement
Lead sponsor: Legacy Health System; Other
Eligibility: 18 Years to 99 Years · Female only
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 3
States / cities: Gresham, Oregon • Portland, Oregon • Tualatin, Oregon

Conditions: Painful Diabetic Neuropathy (PDN)
Interventions: EPT, Drug Placebo Administration, C; Other · Drug
Lead sponsor: Analgesic Solutions; Industry
Eligibility: 18 Years and older
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Natick, Massachusetts

Conditions: Healthy
Interventions: Master Performance Blend Dose 1, Master Performance Blend Dose 2, Performance Energy Blend, Energy Blend, Placebo; Dietary Supplement
Lead sponsor: Miami Research Associates; Network
Eligibility: 18 Years to 40 Years · Male only
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Neoplasms, Breast
Interventions: GSK Biologicals' recombinant WT1 Antigen-Specific Cancer Immunotherapeutic (ASCI) GSK2302024A, Placebo, Aromatase inhibitor, 5-Fluorouracil, Carboplatin AUC, Cyclophosphamide, Docetaxel, Doxorubicin, Epirubicin, Paclitaxel, Trastuzumab; Biological · Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 8
States / cities: Newark, Delaware • Plantation, Florida • Boston, Massachusetts + 5 more

Conditions: Hyperuricemia
Interventions: ALLN-346, Placebo; Drug
Lead sponsor: Allena Pharmaceuticals; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Finger Stiffness, Distal Radius Fracture
Interventions: 500 mg vitamin c, 1 pill per day for 6 weeks, 1 placebo pill for 6 weeks; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 134 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Heart Failure, Healthy Volunteer
Interventions: AMG 986 IV, AMG 986 PO, Placebo PO, Placebo IV; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 182 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2019
U.S. locations: 8
States / cities: Anaheim, California • Tustin, California • Jacksonville, Florida + 5 more

Conditions: Weight Management
Interventions: GS-4571, Placebo, Omeprazole; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 134 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 3
States / cities: Miami, Florida • San Antonio, Texas • Salt Lake City, Utah

Conditions: Cytomegalovirus
Interventions: mRNA-1647, Placebo; Biological · Other
Lead sponsor: ModernaTX, Inc.; Industry
Eligibility: 9 Years to 25 Years
Enrollment: 873 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2026
U.S. locations: 44
States / cities: La Mesa, California • Sacramento, California • Fort Collins, Colorado + 38 more

Conditions: Atherosclerotic Cardiovascular Disease (ASCVD)
Interventions: Pelacarsen, Placebo, Inclisiran; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 246 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 35
States / cities: Birmingham, Alabama • Sun City West, Arizona • Beverly Hills, California + 31 more

Conditions: HIV Coinfection
Interventions: Maraviroc, Placebo; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years and older
Enrollment: 138 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 24
States / cities: Bakersfield, California • Los Angeles, California • Oakland, California + 16 more

Conditions: HIV Infections
Interventions: Sub C gp140 Vaccine, MF59C.1 Adjuvant, Sodium chloride; Biological · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 45 Years
Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2013
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Endothelial Dysfunction, Metabolic Syndrome, Chronic Inflammation
Interventions: UCMSCs, BMMSCs, Placebo; Biological · Other
Lead sponsor: Joshua M Hare; Other
Eligibility: 21 Years to 95 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Acute Exercise, Heat Exposure
Interventions: Menthol Gel, Control Gel; Drug
Lead sponsor: University of Nebraska; Other
Eligibility: 19 Years to 45 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: ADHD, Controls
Interventions: Lidocaine gel, Placebo, Injected lidocaine; Drug
Lead sponsor: PhenoSolve, LLC; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Hepatitis C, HCV, Chronic Hepatitis C Infection, Hepatitis C Genotype 1
Interventions: ABT-450, ABT-072, ABT-333, Ritonavir, Peginterferon alpha-2a, Ribavirin, Placebo; Drug · Other
Lead sponsor: AbbVie (prior sponsor, Abbott); Industry
Eligibility: 18 Years to 65 Years
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 25
States / cities: Phoenix, Arizona • Anaheim, California • La Jolla, California + 19 more

Conditions: Sepsis, Septic Shock
Interventions: Vitamin C, Vitamin B1; Drug
Lead sponsor: Trinity Health Of New England; Other
Eligibility: 18 Years to 90 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Hartford, Connecticut

Search by objective public record fields.

Dose Ranging Trial to Assess Safety and Immunogenicity of V590 (COVID-19 Vaccine) in Healthy Adults (V590-001)

A Study of ORX142 in Healthy Adult Subjects, Including Subjects 18 to 80 Years of Age

Filibuvir In Treatment Naive Hepatitis C Virus (HCV) Genotype 1 Subjects

Anti-Oxidant Treatment of Alzheimer's Disease

Long-term Efficacy, Safety and Tolerability of Iptacopan in C3G or IC-MPGN

HEALEY ALS Platform Trial - Regimen C CNM-Au8

Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of NIO752 in Progressive Supranuclear Palsy

The Use of Pycnogenol® to Alleviate Menopausal Symptoms Induced or Increased by Breast and Gynecological Cancer Treatments

Training "Pain Connoisseurs" for Efficient Analgesic Proof-of-Concept Studies

Pre-Workout on Exercise Performance and Cognition

Evaluation of an Anti-cancer Immunotherapy Combined With Standard Neoadjuvant Treatment in Patients With WT1-positive Primary Invasive Breast Cancer

ALLN-346 Single Ascending Dose (SAD) Study in Healthy Volunteers

Does Vitamin C Reduce Finger Stiffness After Distal Radius Fractures?

Study to Evaluate the Safety and Tolerability of AMG 986 in Healthy Volunteers and Heart Failure Patients

Study of GS-4571 in Healthy Participants, Nondiabetic Obese Participants, and Nonobese Participants With Type 2 Diabetes Mellitus (T2DM)

A Study of mRNA-1647 Cytomegalovirus Vaccine in Healthy Participants 9 to 15 Years of Age and Participants 16 to 25 Years of Age

Lp(a) Lowering Study of Pelacarsen (TQJ230) With Background Inclisiran in Participants With Elevated Lp(a) and Established ASCVD

A Study Of Maraviroc In HIV Co-Infected Subjects With Hepatitis C And/Or Hepatitis B

Evaluating the Safety and Immune Response to an HIV Vaccine Boost Following the Administration of Two HIV Vaccines, in HIV-Uninfected, Healthy Adults (Study Extension to HVTN 073/SAAVI 102)

Infusion of Umbilical Cord Versus Bone Marrow Derived Mesenchymal Stem Cells to Evaluate Cytokine Suppression.

The Influence of Menthol Gel During Exercise With Heat

Validating a New Non-invasive Approach to Testing Lidocaine Effectiveness

A Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072

Vitamin C & Thiamine to Treat Sepsis and Septic Shock